Pediatric Hodgkin Lymphoma: Experience of Hematology department in Casablanca

ibtissam El Bejjaj MD, Nisrine Khoubila Professor, Hajar Maataoui-Belaabes MD, Siham Cherkaoui Professor, Meryem Qachouh Professor, Mohamed Rachid professor, Mouna Lamchahab professor, Abdellah Madani Professor
20th August 1953 hospital, Casablanca, Morocco
Ibn Rochd University Hospital Center, Casablanca, Morocco

INTRODUCTION

Hodgkin's lymphoma (HL) and Non Hodgkin Lymphoma (NHL), are the third most prevalent group of cancers in children.
In the US, they are responsible for 18% of all yearly cancer diagnoses in children and AYAs.
Today, more than 90% of patients are cured, and the 5-year overall survival rate is almost 100%.

AIM


the objective of this work is to describe the epidemiological and clinical aspects of Hodgkin's lymphoma in the pediatric population of our department, as well as the different therapeutic options and their evolution.


METHOD

- **Patients <18 years** diagnosed with HL
- Hematology and Pediatric Oncology department in Casablanca , Morocco
- **January 2016-December 2021**
- Retrospective study
- **Workup :**
  - ✓ Medical history,
  - ✓ Physical examination,
  - ✓ Biopsy with histological study
  - ✓ Standard blood tests,
  - ✓ FDG-PET and/or CT-scan
- **Staging :**
  - ✓ The Ann Arbor staging system
  - ✓ The Lugano classification

RESULTS


- **42 patients** with HL were treated at our center during the above period.
- **Median age** : **11 years**, predominance of **adolescents** [13-17 yo].






- Adenopathies were mostly **unilateral (69%)**
- The median size in long axis **: 3 cm [0,5-5cm]**
- **26%** of adenopathies were Bulky


Biomarker	%
Elevated sedimentation rate	54
Elevated LDH	76
Anemia	35






- Initial pet-scan was performed in : **27 patients(64%)**
- Initial CTAP CT : **15 patients (36%)**
- Mediastinal enlargement was found in **5 patients (12%).**

Histological type	%
Sclero nodular	84
Mixed cellularity	10
Rich in lymphocytes	5
Poppema	1



- Being progressive, 2 patients received 3 lines of treatment, and 2 patients 4 lines.
- One patient presented with Lyell's syndrome following his treatment (BENDAGEV).



CONCLUSIONS

Hodgkin lymphoma treatment innovations have increased survival rates in children, adolescents, and young adults by more than 90%. However, the possibility of late toxicity is still a major issue for HL survivors, and the goal of contemporary research has been to increase cure rates while lowering long-term toxicity.

REFERENCES

1- Dourthe, Marie Emilie, et al. "Recommandations de la SFCE pour la prise en charge du lymphome de Hodgkin nodulaire à prédominance lymphocytaire de l'enfant et de l'adolescent." *Bulletin du Cancer* (2023).

2-- Belsky, Jennifer A., Jessica Hochberg, and Lisa Giulino-Roth. "Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults." *Best Practice & Research Clinical Haematology* (2023): 101445.

3- Gómez-Almaguer, David, et al. "Treatment of classical Hodgkin's lymphoma in children and adolescents." *Expert Opinion on Pharmacotherapy* 20.10 (2019): 1227-1234.